Skip to content

Neuroimaging Study

Neuroimaging Study

Status
Enrolling by invitation
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03618186
Enrollment
240
Registered
2018-08-07
Start date
2018-11-26
Completion date
2030-05-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Keywords

African Americans, neurological exam, Dementia, Alzheimer's Disease

Brief summary

The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.

Interventions

COMBINATION_PRODUCTTau PET scan

Patient will receive a dose of flutaucipir and be scanned appropriately

Sponsors

Mayo Clinic
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female African Americans 30 years of age or older * Subjects who have completed or are scheduled to undergo the neurological evaluation procedures described below.

Exclusion criteria

* Subjects unable to lie down without moving for 20 minutes. * Women who are pregnant or cannot stop breast feeding for 24 hours. * Claustrophobic patients unable to tolerate the scans. * Subjects with a prolonged QT interval (as demonstrated by ECG test) cannot participate in the Tau-PET scans. * Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc, since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI.

Design outcomes

Primary

MeasureTime frameDescription
Tau positive scans5 yearsPercentage of each of the three groups with tau positive scans

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNeill R Graff-Radford, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026